Jpmorgan Chase & CO Celcuity Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Celcuity Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12,007 shares of CELC stock, worth $138,440. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,007
Previous 23,619
49.16%
Holding current value
$138,440
Previous $386,000
53.63%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CELC
# of Institutions
107Shares Held
30.4MCall Options Held
30.8KPut Options Held
152K-
Bvf Inc San Francisco, CA3.47MShares$40 Million1.64% of portfolio
-
Perceptive Advisors LLC New York, NY2.36MShares$27.2 Million0.92% of portfolio
-
Baker Bros. Advisors LP New York, NY1.87MShares$21.6 Million0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$18.8 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA1.54MShares$17.7 Million0.4% of portfolio
About Celcuity Inc.
- Ticker CELC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,941,300
- Market Cap $172M
- Description
- Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...